Coya Therapeutics, Inc. (NASDAQ:COYA) Sees Large Increase in Short Interest

Coya Therapeutics, Inc. (NASDAQ:COYA) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 209,200 shares, a growth of 10.2% from the December 15th total of 189,800 shares. Based on an average daily volume of 92,500 shares, the short-interest ratio is currently 2.3 days. Currently, 1.4% of the company’s shares are sold short.

Coya Therapeutics Stock Performance

COYA stock traded down $0.22 during mid-day trading on Friday, hitting $5.38. 63,988 shares of the company were exchanged, compared to its average volume of 51,707. Coya Therapeutics has a 1-year low of $4.75 and a 1-year high of $10.69. The firm’s 50 day simple moving average is $6.02 and its 200 day simple moving average is $6.49. The firm has a market cap of $89.88 million, a P/E ratio of -8.28 and a beta of 0.46.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.15. On average, equities research analysts predict that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

COYA has been the subject of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a report on Monday, November 11th. Chardan Capital restated a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research report on Thursday, November 7th. Finally, D. Boral Capital reiterated a “buy” rating and set a $15.00 target price on shares of Coya Therapeutics in a report on Wednesday, December 18th.

Insider Transactions at Coya Therapeutics

In related news, CEO Arun Swaminathan purchased 5,000 shares of the stock in a transaction dated Monday, November 11th. The stock was bought at an average cost of $7.34 per share, with a total value of $36,700.00. Following the purchase, the chief executive officer now directly owns 5,000 shares in the company, valued at $36,700. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Insiders have purchased 9,510 shares of company stock worth $69,615 in the last three months. Insiders own 12.00% of the company’s stock.

Institutional Trading of Coya Therapeutics

Institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC bought a new position in shares of Coya Therapeutics during the second quarter worth about $101,000. GHP Investment Advisors Inc. acquired a new position in Coya Therapeutics during the 3rd quarter worth approximately $169,000. Finally, Geode Capital Management LLC grew its stake in shares of Coya Therapeutics by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after acquiring an additional 4,485 shares in the last quarter. 39.75% of the stock is currently owned by institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.